MIS Stock Chart & Stats
€0.38
>-€0.01(-0.52%)
At close: 4:00 PM EDT
€0.38
>-€0.01(-0.52%)
Day’s Range― - ―
52-Week Range€0.32 - €0.53
Previous CloseN/A
Volume0.00
Average Volume (3M)37.00
Market Cap
€188.87M
Enterprise Value€477.57
Total Cash (Recent Filing)€8.84M
Total Debt (Recent Filing)€199.62M
Price to Earnings (P/E)40.1
Beta0.94
Next Earnings
Feb 25, 2027EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding389,634,830
10 Day Avg. Volume110
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)1.13
Price to Sales (P/S)1.05
P/FCF Ratio38.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.48Price Target Upside25.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.03
Revenue Forecast (FY)€174.17M
Bulls Say, Bears Say
Bulls Say
Integrated Fertility ServicesMVF’s integrated model spans clinical treatment, reproductive diagnostics and laboratory work within the fertility pathway. This broad service offering can deepen patient relationships, support revenue across multiple stages of care, and reinforce the company’s role in a specialist healthcare market over the medium term.
Long-term Revenue GrowthDespite recent moderation, the multi-year revenue trajectory shows that MVF has expanded its business scale and retained positive top-line growth. Continued revenue generation provides a base for operating leverage and supports investment in clinics, laboratories and specialist fertility services.
Meaningful Equity BaseA substantial equity base provides MVF with an important balance-sheet foundation relative to its asset base. This capital cushion can help absorb earnings volatility and preserve financial flexibility, even though leverage has risen and returns on equity have weakened materially.
Bears Say
Sharp Margin CompressionThe steep decline in gross and net margins indicates materially weaker profitability and reduced earnings conversion from revenue. If this performance persists, MVF may have less capacity to fund growth, absorb cost pressures and generate attractive returns from its existing operating footprint.
Materially Higher LeverageMVF’s substantially higher debt burden reduces financial flexibility and increases the importance of maintaining reliable earnings and cash generation. Greater leverage can constrain capital allocation and leave the company less able to absorb further operating weakness or profitability volatility.
Weak And Inconsistent Free Cash FlowThe latest free-cash-flow outcome is weak relative to reported earnings, and the pack describes cash conversion as inconsistent. This reduces the quality of near-term earnings, limits internally generated funding for investment or debt reduction, and increases sensitivity to future cash-flow volatility.
Monash IVF Group Ltd News
MIS FAQ
What was Monash IVF Group Ltd’s price range in the past 12 months?
Monash IVF Group Ltd lowest stock price was €0.32 and its highest was €0.53 in the past 12 months.
What is Monash IVF Group Ltd’s market cap?
Monash IVF Group Ltd’s market cap is €188.87M.
When is Monash IVF Group Ltd’s upcoming earnings report date?
Monash IVF Group Ltd’s upcoming earnings report date is Feb 25, 2027 which is in 162 days.
How were Monash IVF Group Ltd’s earnings last quarter?
Monash IVF Group Ltd released its earnings results on Aug 30, 2026. The company reported €0.009 earnings per share for the quarter, missing the consensus estimate of €0.014 by -€0.005.
Is Monash IVF Group Ltd overvalued?
According to Wall Street analysts Monash IVF Group Ltd’s price is currently Undervalued.
Does Monash IVF Group Ltd pay dividends?
Monash IVF Group Ltd does not currently pay dividends.
What is Monash IVF Group Ltd’s EPS estimate?
Monash IVF Group Ltd’s EPS estimate is 0.02.
How many shares outstanding does Monash IVF Group Ltd have?
Monash IVF Group Ltd has 389,634,830 shares outstanding.
What happened to Monash IVF Group Ltd’s price movement after its last earnings report?
Monash IVF Group Ltd reported an EPS of €0.009 in its last earnings report, missing expectations of €0.014. Following the earnings report the stock price went down -0.517%.
Which hedge fund is a major shareholder of Monash IVF Group Ltd?
Currently, no hedge funds are holding shares in DE:MIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monash IVF Group Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.48 (25.84% Upside)
€0.48 (25.84% Upside)
Blogger Sentiment
Bullish
DE:MIS Sentiment 100%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.97%
12-Months-Change
Fundamentals
Return on Equity
3.31%
Trailing 12-Months
Asset Growth
4.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Monash IVF Group Ltd
Founded in 2014 and headquartered in Richmond, Australia, Monash IVF Group Limited delivers specialized reproductive assistance and women's imaging services. Its operations span Australia and Malaysia, offering a broad spectrum of care. This includes diagnostic obstetric and gynecological ultrasound examinations, a range of fertility treatments, and advanced tertiary-level prenatal diagnostics. The company is also a key provider of in-vitro fertilization (IVF) services.
MIS Stock 12 Month Forecast
Average Price Target
€0.48
▲(25.84% Upside)
Technical Analysis
―
Healius Limited
―
Cryosite Limited
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―